Ignite Creation Date:
2025-12-24 @ 10:51 PM
Ignite Modification Date:
2025-12-25 @ 8:20 PM
Study NCT ID:
NCT04303169
Status:
COMPLETED
Last Update Posted:
2025-10-27
First Post:
2020-03-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-06-26
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-09-24
Completion Date Type:
ACTUAL
First Submit Date:
2020-03-09
First Submit QC Date:
None
Study First Post Date:
2020-03-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-23
Last Update Post Date:
2025-10-27
Last Update Post Date Type:
ESTIMATED